Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients

Study Overview
=================
Brief Summary
-----------------
Despite being standard of care, there are still many medical requirements related to immune checkpoint blocker based therapies such as identify patients susceptible to respond with the less adverse events, evaluate the clinical benefit of adjuvant treatment /risk of relapse and design new strategies for non-responder patients. Thus, this project aims at understanding the impact of anti-PD1 on the immune system through investigation of the phenotypic, functional, metabolic and transcriptomic profiles of circulating DC subsets and effectors in response to anti-PD1 therapy in melanoma patients. The primary objective of the study is to identify the biomarkers of response to anti-PD1 according to the type of patient before the start of the treatment.

Official Title
-----------------
Phenotypic, Functional, Metabolic and Transcriptomic Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients

Conditions
-----------------
Melanoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with histologically confirmed melanoma (stage I, II, III or IV based on AJCC classification) Able to sign the informed collection consent for the retrospective part or to express their non-opposition to the research for the prospective part of the study Exclusion Criteria: Subject under guardianship or subject deprived of freedom Persons benefiting from special protection (as defined in Articles L1121-5 and L1121-8 of the Public Health Code): minors, pregnant or breastfeeding women, adults protected by law (under guardianship, curatorship or deprived of liberty) and persons hospitalized without their consent (as defined in Articles L3212-1 and L3212-3 of the Public Health Code). ocular melanoma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort #A<br>monotherapy anti-PD1 first line | |
| Cohort #B<br>monotherapy anti-PD1 second line | |
| Cohort #C<br>monotherapy anti-PD1 adjuvant | |
| Cohort #D<br>combotherapy anti-PD1/CTLA-4 first line | |
| Cohort #E<br>untreated stage I and II melanoma patient | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of biomarkers of response to anti6PD1 according to the type of patient before the start of treatment | response to treatment according to immunological parameters at T0 between patients responding (R), stable (SD) and non-responding (NR) to treatment | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| identification of early biomarkers predictive of the response to anti-PD1 | comparison of immunological parameters according to the type of patients (R, SD and NR) for each time point | at each time point (3, 4 or 6 weeks) |